Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sodium stibogluconate + allopurinol
- Development stage
- Preclinical
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of sodium stibogluconate (an antimonial compound) and allopurinol used primarily for the treatment of various forms of leishmaniasis, including cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL). Sodium stibogluconate is typically administered intravenously at a dose of 20mg/kg with a maximum of 850mg/day, while allopurinol dosing varies from 100mg daily to 20mg/kg daily depending on the treatment protocol.
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on sodium stibogluconate + allopurinol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sodium stibogluconate + allopurinol.